Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Sees Significant Decline in Short Interest

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) saw a significant decline in short interest in December. As of December 15th, there was short interest totalling 2,700 shares, a decline of 57.8% from the November 30th total of 6,400 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 20,000 shares, the short-interest ratio is currently 0.1 days.

Analyst Ratings Changes

Separately, Benchmark restated a “speculative buy” rating and issued a $8.00 price target on shares of Anebulo Pharmaceuticals in a research report on Tuesday, November 19th.

Insider Activity

In other Anebulo Pharmaceuticals news, Director Aron R. English bought 10,101,010 shares of the business’s stock in a transaction on Monday, December 23rd. The stock was purchased at an average cost of $0.99 per share, for a total transaction of $9,999,999.90. Following the completion of the purchase, the director now directly owns 15,467,300 shares of the company’s stock, valued at approximately $15,312,627. This trade represents a 188.23 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 85.90% of the stock is owned by company insiders.

Anebulo Pharmaceuticals Stock Up 4.9 %

ANEB traded up $0.08 during midday trading on Friday, hitting $1.70. 90,542 shares of the company were exchanged, compared to its average volume of 10,916. The firm’s 50 day moving average price is $1.57 and its 200-day moving average price is $1.93. Anebulo Pharmaceuticals has a 1-year low of $0.80 and a 1-year high of $3.30. The firm has a market capitalization of $44.09 million, a P/E ratio of -5.67 and a beta of -1.09.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last released its earnings results on Wednesday, September 25th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.08. On average, sell-side analysts predict that Anebulo Pharmaceuticals will post -0.52 earnings per share for the current fiscal year.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.